Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. - Wikidata - wikimedia - TriplyDB

Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.

Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.

http://www.wikidata.org/entity/Q34243432

about

The Potential Role of Nitric Oxide in Halting Cancer Progression Through Chemoprevention Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues Spotlights on immunological effects of reactive nitrogen species: When inflammation says nitric oxide Myeloid-derived cells are key targets of tumor immunotherapy Coordinated regulation of myeloid cells by tumours Contribution of the Microenvironmental Niche to Glioblastoma Heterogeneity.Plasma levels of nitrate and risk of prostate cancer: a prospective study Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages Multifaceted antitumor responses to activating anti-CD40 antibody therapy combined with immunomodulatory or targeted agents.Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.Development of individualized anti-metastasis strategies by engineering nanomedicines Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects Nitric oxide-mediated regulation of β-amyloid clearance via alterations of MMP-9/TIMP-1 Thiol Modification By Pharmacologically Active Agents of the Diazeniumdiolate Class Proteomic analysis of the NOS2 interactome in human airway epithelial cells Resistance of LPS-activated bone marrow derived macrophages to apoptosis mediated by dexamethasone Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.Macrophages in cancer and infectious diseases: the 'good' and the 'bad'.The yin and yang of nitric oxide in cancer progression.Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.Type 2 cytokines: mechanisms and therapeutic strategies.T cells in tumor microenvironment.T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.AP-2α suppresses invasion in BeWo cells by repression of matrix metalloproteinase-2 and -9 and up-regulation of E-cadherin.STAT of the union: dynamics of distinct tumor-associated macrophage subsets governed by STAT1.Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors.Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer.Impact of the reactive microenvironment on the bone marrow involvement of follicular lymphoma.Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro.Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy.Molecular signature of nitric oxide on major cancer hallmarks of colorectal carcinoma.Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.The (CCTTT)n microsatellite polymorphism in the NOS2 gene may influence lung cancer risk and long-term survival, especially in non-smokers

P2860

Q26751142-F0B12D9B-97AB-49DB-849A-7E6EAB0B0DAA Q26765758-9E593DDD-6636-4324-9DEB-988E1B80BBCC Q27003907-9E0EC124-7661-4003-97CB-E51DBD44A359 Q27694770-D1CF08E2-3E09-49F1-B289-A4885DBE8131 Q28388246-60DB145C-CC86-4FD0-B490-E2C961CEA199 Q28395157-9465097D-67AC-4F81-964A-7E09557A7E04 Q33786677-31AEB3AC-4C2D-476A-9E38-DD36277B40FD Q34036770-CB978781-4518-47C2-AC3B-5A8103AFB346 Q34044797-AA2C55C7-20E5-4572-8C9E-2BABBA73FFA4 Q34934017-5F29566D-6A8F-4862-A22D-70878DD154CB Q35546925-FB509C92-2B12-484D-831D-F24B148FC7A3 Q35967474-BD95AD0C-BF27-4CE5-A02D-4FB05AF9140A Q36016640-B86A76AE-E052-482D-9E9C-E5DA9D2B35D0 Q36322948-1AE4E7F9-EF40-4672-9408-2E964952D29F Q36610868-C23B1BA9-9C42-4D63-BD9A-55C0889061C1 Q36735832-94F9800F-63F9-4995-9BCC-7A73C4B68DE0 Q36754617-FE582189-24AA-45C8-AA6C-731195AEEE08 Q37161361-D1D8A18C-E037-4232-8D0F-E15A2C0944C9 Q37628186-2AD302D4-155A-4BB7-9C2E-07886A08D746 Q37829504-FDAA42B4-9F68-40E3-8DB9-DB74A91E6D34 Q37945300-B50CD02C-3A8D-43C9-94DD-1FD37DE7B744 Q38077081-37061958-F2E6-4368-86A5-63B074AB43A4 Q38153283-D88CB683-FB83-4BC5-B88D-33612CCC0271 Q38424752-92CC8DDB-3FDD-4D36-938B-0B609C939B90 Q38609942-D3664231-CCB6-4DD0-8189-39E39F40E067 Q38746598-8A58D87E-EC64-4F71-BD82-0B023306476A Q39154049-15BD4E83-DC71-4730-A33B-5E6C579E2F04 Q39168056-90B01BD6-D7A8-4E3D-96D9-F9B899899187 Q39418532-18375182-BC17-478B-A723-57D2E83F0D33 Q39543819-960AF14E-728E-4995-BF85-F87CFE65587A Q40025028-1DE9A67D-6D2F-4967-8582-61BAB629FA6E Q41011622-3F4F8B87-05D6-44BA-AA20-659A12279239 Q43428464-289E27B5-D47E-4456-A04D-08172591242D Q48638999-0DE398F6-A94B-4939-88D7-05FAF1E8065B Q49383041-4294F87C-0A34-4B4F-A9A4-E112165149AD Q53179258-FA3741AC-17F4-48DE-96B3-DD1B445427F4 Q57011093-9595D145-ED2B-4213-891D-887344DE3B7B

P2860

Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.

http://www.wikidata.org/entity/Q34243432

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Macrophage-dependent nitric ox ...... IL-2/anti-CD40 immunotherapy.

@ast

Macrophage-dependent nitric ox ...... IL-2/anti-CD40 immunotherapy.

@en

Macrophage-dependent nitric ox ...... IL-2/anti-CD40 immunotherapy.

@nl

type

label

Macrophage-dependent nitric ox ...... IL-2/anti-CD40 immunotherapy.

@ast

Macrophage-dependent nitric ox ...... IL-2/anti-CD40 immunotherapy.

@en

Macrophage-dependent nitric ox ...... IL-2/anti-CD40 immunotherapy.

@nl

prefLabel

Macrophage-dependent nitric ox ...... IL-2/anti-CD40 immunotherapy.

@ast

Macrophage-dependent nitric ox ...... IL-2/anti-CD40 immunotherapy.

@en

Macrophage-dependent nitric ox ...... IL-2/anti-CD40 immunotherapy.

@nl

P1433

Q34243432-0CF69341-E918-4940-83FF-4498491EEAF2

P1476

Q34243432-31C966B4-1ACC-487A-BE2C-EDF41B04E636

P2093

Q34243432-0FF2AF73-E77D-41FC-B68B-F10C845A212D

Q34243432-2800ED3B-27C8-437B-A636-BEBC7C021ADE

Q34243432-32319FEA-2370-4943-9FE2-AAE5C784515D

Q34243432-3445F750-A1A1-45AF-AA64-EFA0DE3CE349

Q34243432-7D2902C7-A6DA-42A1-905D-3C5B9CA1AE16

Q34243432-93384A94-11E8-4D1D-B55A-EFA7A3F45A4D

Q34243432-935C88A9-A429-4D37-BA59-E6392167B22D

Q34243432-B790E418-C556-4F1C-B72C-B9A7CE120267

Q34243432-D5995665-D45A-4DBE-BA9E-836033ABEDCF

Q34243432-DCCBCC96-BC0F-4301-8A07-43F071F5A520

P2860

Q34243432-06736FD4-5818-4F1A-A29D-3A4FB3BD47F6

Q34243432-1160AF8E-B396-4B83-B42C-7B17A4C72107

Q34243432-211CD200-4331-4B34-A84D-9022DFFA3E0C

Q34243432-339BD5AA-3575-44FB-9BF6-87620AD82D18

Q34243432-392ECE11-087F-4C7B-9830-620C41F7DE98

Q34243432-39D689B1-7E3E-4D75-B4E3-5A1E5F47C1D8

Q34243432-51AB33F3-6880-45FB-BEB5-075B7D009227

Q34243432-528D26D1-BAA5-4201-8829-CAC94FEE59EA

Q34243432-5802AF71-E784-4F67-9323-90A86BC90115

Q34243432-5BB0B9F0-1B45-4EC4-828B-4AE5F275EB8B

P304

Q34243432-F2C4E6FB-B8C6-4C46-B76F-1DADF264C256

P31

Q34243432-23B3CB57-6473-4CA7-86BA-82026BEC768E

P356

Q34243432-3C51C26F-EC31-4798-A8F9-8490018A8095

P407

Q34243432-6A555D58-2B6B-4D7E-8816-F424A4AD4993

P433

Q34243432-94E5DC60-689B-4C17-A460-E88774C4DC62

P478

Q34243432-F94D7A39-3370-4FA1-9B2F-56903C3EDC03

P50

Q34243432-A7BB3F5C-2906-4BBD-A693-8E60674BBEED

P577

Q34243432-EB705030-8F81-4E89-904E-596E3BBF07D2

P5875

Q34243432-C6CB40D5-559B-43CD-B963-A5CF66AAF2AA

P698

Q34243432-99961017-DA99-4BDA-A666-5B4CDB06BD7D

P921

Q34243432-05F44419-1B91-4F8F-8232-154BB2B036B9

Q34243432-9AA90AE5-A689-401D-B6AA-4987DE969170

P932

Q34243432-2B0436DF-5E18-4641-B438-5A6225578B82

P356

P1433

Journal of Experimental Medicine

P1476

Macrophage-dependent nitric ox ...... r IL-2/anti-CD40 immunotherapy

@en

P2093

Anna E Maciag

http://www.w3.org/2001/XMLSchema#string

Curtis C Harris

http://www.w3.org/2001/XMLSchema#string

David A Wink

http://www.w3.org/2001/XMLSchema#string

Jonathan M Weiss

http://www.w3.org/2001/XMLSchema#string

Larry K Keefer

http://www.w3.org/2001/XMLSchema#string

Lisa A Ridnour

http://www.w3.org/2001/XMLSchema#string

Peijun He

http://www.w3.org/2001/XMLSchema#string

Robert H Wiltrout

http://www.w3.org/2001/XMLSchema#string

Tim Back

http://www.w3.org/2001/XMLSchema#string

William J Murphy

http://www.w3.org/2001/XMLSchema#string

P2860

A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy

Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors.

Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide.

Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma.

Nitric oxide is an important mediator for tumoricidal activity in vivo

Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.

Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways

P304

2455-2467

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20100670

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

207

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47336483

http://www.w3.org/2001/XMLSchema#string

P698

20921282

http://www.w3.org/2001/XMLSchema#string

P921

P932

2964582

http://www.w3.org/2001/XMLSchema#string